CLINICAL TRIALS PROFILE FOR MYCOSTATIN
✉ Email this page to a colleague
All Clinical Trials for MYCOSTATIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00942526 ↗ | Oral Anti-Infective Agent for Esophageal Anastomotic Leakage | Unknown status | National Taiwan University Hospital | Phase 2 | 2009-06-01 | Anastomotic leakage is still to be a major cause of considerable morbidity and mortality after esophagectomy and gastric pull up for esophageal carcinoma. Risk factor analyses of anastomotic leakage, including blood supply, graft tension, and comorbidity, have been performed, but few studies have produced strategies that have improved operative results. This study will be performed to identify prognostic variables that might be used to develop a strategy for optimizing outcomes after esophagogastrectomy. |
| NCT01495039 ↗ | Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients | Completed | Policlinico Hospital | Phase 4 | 2008-11-01 | Purpose. Oral chemoprophylaxis has been advocated to reduce the incidence of Candida colonization and infection. However, Candida prophylaxis in intensive care unit (ICU) is still a matter of debate. Methods. Randomized, single-center trial studying single drug (nystatin) versus control in surgical ICU patients. Multiple-site testing for fungi were performed in each patient at ICU admission (T0) and subsequently every 3 days (T3, T6, T9…). The primary evaluation criterion was the time course of colonization index (CI) during ICU stay. |
| NCT02166450 ↗ | Effects of Denture-Related Stomatitis on Blood Pressure in Denture Wearers | Unknown status | Jagiellonian University | 2011-10-01 | The aim of this study is to evaluate the influence of presence of oral fungal infection, which leads to denture-related stomatitis, on blood pressure, endothelial function and immune cell phenotype in patients wearing dentures. | |
| NCT03390374 ↗ | Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants | Completed | Dr Cipto Mangunkusumo General Hospital | Phase 4 | 2010-10-01 | This study determines the effectiveness of oral nystatin as prophylaxis in order to prevent systemic fungal infection in very low birth weight preterm neonates. 47 participants received oral nystatin and 48 participants received sterile water as part of oral hygiene. |
| NCT03862079 ↗ | Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics | Withdrawn | National Cancer Institute (NCI) | Phase 2 | 2020-06-01 | This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics. Fecal microbiota transplantation is the administration by enema of fecal matter (stool) that includes helpful bacteria from a normal, healthy donor. Total gut decontamination uses antibiotics to remove/reduce the amount of bacteria in the digestive system. It is not yet known if a fecal microbiota transplant with or without total gut decontamination works better in preventing graft versus host disease compared to standard immunosuppressive therapies (therapies that lower the normal function of the immune system). |
| NCT03862079 ↗ | Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics | Withdrawn | M.D. Anderson Cancer Center | Phase 2 | 2020-06-01 | This phase II trial studies how well a fecal microbiota transplant with or without total gut decontamination works in preventing graft versus host disease in patients exposed to broad-spectrum antibiotics. Fecal microbiota transplantation is the administration by enema of fecal matter (stool) that includes helpful bacteria from a normal, healthy donor. Total gut decontamination uses antibiotics to remove/reduce the amount of bacteria in the digestive system. It is not yet known if a fecal microbiota transplant with or without total gut decontamination works better in preventing graft versus host disease compared to standard immunosuppressive therapies (therapies that lower the normal function of the immune system). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MYCOSTATIN
Condition Name
Clinical Trial Locations for MYCOSTATIN
Trials by Country
Clinical Trial Progress for MYCOSTATIN
Clinical Trial Phase
Clinical Trial Sponsors for MYCOSTATIN
Sponsor Name
